 LAVAL, Québec, April 20, 2020 GLOBE NEWSWIRE -- Acasti Pharma Inc. Acasti or the Company NASDAQ: ACST TSX-V: ACST, a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre omega-3 phospholipid for the treatment of severe hypertriglyceridemia, today announced that it has received a Notice of Allowance for its second composition matter patent to be awarded by the Canadian Intellectual Property Office. This new patent expands the Companys existing claims to include any composition containing EPA and DHA, where at least 50 of the composition consists of phospholipids. 